losartan has been researched along with Cardiomyopathies in 32 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiac fibrosis is a severe condition with limited therapeutic options and often occurs in chronic cardiovascular diseases such as hypertension and myocardial infarction." | 5.72 | Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis. ( Chen, W; Han, L; Ji, H; Yu, L; Zhu, H, 2022) |
| "Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice." | 5.37 | Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 5.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| " Methods Baseline and follow-up clinical and echocardiographic parameters were assessed in 939 hypertensive patients with electrocardiogram (ECG) LVH participating in the Losartan Intervention for Endpoint reduction in hypertension (LIFE) echocardiography substudy (66±7 years; 42% women; 11% with diabetes) who did not have aortic or mitral valve stenosis or prosthesis." | 3.79 | Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study. ( Boman, K; Casalnuovo, G; Dahlöf, B; De Marco, M; de Simone, G; Devereux, RB; Gerdts, E; Kizer, JR; Migliore, T; Olsen, MH; Wachtell, K, 2013) |
| " The aim of this work was to assess the impact of hemin (heme oxygenase-1 inducer) on NADPH oxidase activation, cardiac oxidative stress, and development of fibrosis in a rat model of renovascular hypertensive cardiomyopathy in comparison to an anti-hypertensive reference treatment with losartan." | 3.77 | Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. ( Belmokhtar, K; Bonnet, P; Eder, V; Khamis, G; Machet, MC; Vourc'h, P; Worou, ME, 2011) |
| " This case report presents the successful treatment of severe heart failure with prednisone, glycosides and an angiotensin-1 receptor antagonist." | 3.70 | [Heart failure as a cardiac symptom of sarcoidosis. Successful treatment of heart failure with steroids, digitalis and an angiotensin-1-receptor antagonist in sarcoidosis]. ( Erbel, R; Kuntz, S; Oldenburg, O; Philipp, T; Sack, S; Schäfers, RF; Weber, F, 2000) |
| "The dystrophinopathies include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM)." | 2.58 | Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy. ( Bourke, JP; Bueser, T; Quinlivan, R, 2018) |
| "Cardiac fibrosis is a severe condition with limited therapeutic options and often occurs in chronic cardiovascular diseases such as hypertension and myocardial infarction." | 1.72 | Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis. ( Chen, W; Han, L; Ji, H; Yu, L; Zhu, H, 2022) |
| "Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice." | 1.37 | Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. ( Gordish-Dressman, H; Guerron, AD; Hoffman, EP; Iantorno, M; Nagaraju, K; Rayavarapu, S; Sali, A; Spurney, CF; van der Meulen, J; Yu, Q, 2011) |
| "Losartan treatment resulted in improvement of myocardial function and suppressed cardiac and renal fibrosis compared with the diabetic group." | 1.35 | Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. ( Aizawa, Y; Arozal, W; Kodama, M; Ma, M; Suzuki, K; Tachikawa, H; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K, 2009) |
| "Celiac disease is associated frequently with iron deficiency anemia, dermatitis herpetiformis, selective IgA deficiency, thyroid disorders, diabetes mellitus, and various connective tissue disorders but is rarely associated with cardiomyopathy." | 1.33 | Cardiomyopathy associated with celiac disease. ( Goel, NK; Kamath, PS; McBane, RD, 2005) |
| "Losartan treatment was associated with significant attenuation of MMP activities in cardiomyopathic samples at 65 and 120 days." | 1.30 | Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. ( Dixon, IM; Jasmin, G; Ju, H; Reid, NL; Scammell-La Fleur, T; Werner, JP, 1997) |
| "Losartan treatment decreased systolic pressure and yellow-red collagen fiber content in all areas, whereas spironolactone treatment decreased green collagen fiber content without decreasing systolic pressure." | 1.29 | Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. ( Appay, MD; Bariety, J; Heudes, D; Hinglais, N; Michel, JB; Nicoletti, A; Philippe, M; Sassy-Prigent, C, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (12.50) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 6 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Kovács, ZZA | 2 |
| Szűcs, G | 2 |
| Freiwan, M | 2 |
| Kovács, MG | 2 |
| Márványkövi, FM | 1 |
| Dinh, H | 2 |
| Siska, A | 2 |
| Farkas, K | 1 |
| Kovács, F | 2 |
| Kriston, A | 2 |
| Horváth, P | 2 |
| Kővári, B | 1 |
| Cserni, BG | 1 |
| Cserni, G | 2 |
| Földesi, I | 2 |
| Csont, T | 2 |
| Sárközy, M | 2 |
| Yokota, T | 1 |
| Koiwa, H | 1 |
| Matsushima, S | 1 |
| Tsujinaga, S | 1 |
| Naya, M | 1 |
| Morisaki, H | 1 |
| Morisaki, T | 1 |
| Losonczi, R | 1 |
| Dux, L | 1 |
| Chen, XS | 1 |
| Wang, SH | 1 |
| Liu, CY | 1 |
| Gao, YL | 1 |
| Meng, XL | 1 |
| Wei, W | 1 |
| Shou, ST | 1 |
| Liu, YC | 1 |
| Chai, YF | 1 |
| Zhu, H | 1 |
| Ji, H | 1 |
| Chen, W | 1 |
| Han, L | 1 |
| Yu, L | 1 |
| Wang, EY | 1 |
| Kuzmanov, U | 1 |
| Smith, JB | 1 |
| Dou, W | 1 |
| Rafatian, N | 1 |
| Lai, BFL | 1 |
| Lu, RXZ | 1 |
| Wu, Q | 1 |
| Yazbeck, J | 1 |
| Zhang, XO | 1 |
| Sun, Y | 1 |
| Gramolini, A | 1 |
| Radisic, M | 1 |
| Bourke, JP | 1 |
| Bueser, T | 1 |
| Quinlivan, R | 1 |
| Chamorro-Pareja, N | 1 |
| Marin-Acevedo, JA | 1 |
| Chirilă, RM | 1 |
| Meyers, TA | 1 |
| Heitzman, JA | 1 |
| Krebsbach, AM | 1 |
| Aufdembrink, LM | 1 |
| Hughes, R | 1 |
| Bartolomucci, A | 1 |
| Townsend, D | 1 |
| Poletto Bonetto, JH | 1 |
| Fernandes, RO | 1 |
| Dartora, DR | 1 |
| Flahault, A | 1 |
| Sonea, A | 1 |
| He, Y | 1 |
| Cloutier, A | 1 |
| Belló-Klein, A | 1 |
| Nuyt, AM | 1 |
| Liu, Q | 1 |
| Lu, D | 1 |
| Wang, S | 1 |
| Wang, K | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Fang, P | 1 |
| Li, Z | 1 |
| Geng, J | 1 |
| Shan, Q | 1 |
| Matsuhisa, S | 1 |
| Otani, H | 1 |
| Okazaki, T | 1 |
| Yamashita, K | 1 |
| Akita, Y | 1 |
| Sato, D | 1 |
| Moriguchi, A | 1 |
| Iwasaka, T | 2 |
| De Mello, WC | 3 |
| Gerena, Y | 1 |
| Arozal, W | 1 |
| Watanabe, K | 2 |
| Veeraveedu, PT | 1 |
| Ma, M | 2 |
| Thandavarayan, RA | 1 |
| Suzuki, K | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 2 |
| Aizawa, Y | 2 |
| Spurney, CF | 1 |
| Sali, A | 1 |
| Guerron, AD | 1 |
| Iantorno, M | 1 |
| Yu, Q | 1 |
| Gordish-Dressman, H | 1 |
| Rayavarapu, S | 1 |
| van der Meulen, J | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Worou, ME | 1 |
| Belmokhtar, K | 1 |
| Bonnet, P | 1 |
| Vourc'h, P | 1 |
| Machet, MC | 1 |
| Khamis, G | 1 |
| Eder, V | 1 |
| De Marco, M | 1 |
| Gerdts, E | 1 |
| Casalnuovo, G | 1 |
| Migliore, T | 1 |
| Wachtell, K | 1 |
| Boman, K | 1 |
| Dahlöf, B | 1 |
| Olsen, MH | 1 |
| Kizer, JR | 1 |
| Devereux, RB | 1 |
| de Simone, G | 1 |
| Shibasaki, Y | 1 |
| Nishiue, T | 1 |
| Masaki, H | 1 |
| Matsubara, H | 1 |
| Peng, J | 1 |
| Gurantz, D | 1 |
| Tran, V | 1 |
| Cowling, RT | 1 |
| Greenberg, BH | 1 |
| Monterrubio, J | 1 |
| Goel, NK | 1 |
| McBane, RD | 1 |
| Kamath, PS | 1 |
| Escobales, N | 2 |
| Crespo, MJ | 4 |
| Altieri, PI | 1 |
| Gurusamy, N | 1 |
| Prakash, P | 1 |
| Hirabayashi, K | 1 |
| Zhang, S | 1 |
| Muslin, AJ | 1 |
| Simões, MV | 1 |
| Marin-Neto, JA | 1 |
| Romano, MM | 1 |
| O'Connell, JL | 1 |
| de Santi, GL | 1 |
| Maciel, BC | 1 |
| Lambert, C | 1 |
| Massillon, Y | 1 |
| Meloche, S | 1 |
| Nicoletti, A | 1 |
| Heudes, D | 1 |
| Hinglais, N | 1 |
| Appay, MD | 1 |
| Philippe, M | 1 |
| Sassy-Prigent, C | 1 |
| Bariety, J | 1 |
| Michel, JB | 1 |
| Dixon, IM | 1 |
| Ju, H | 1 |
| Reid, NL | 1 |
| Scammell-La Fleur, T | 1 |
| Werner, JP | 1 |
| Jasmin, G | 1 |
| Varo, N | 1 |
| Etayo, JC | 1 |
| Zalba, G | 1 |
| Beaumont, J | 1 |
| Iraburu, MJ | 1 |
| Montiel, C | 1 |
| Gil, MJ | 1 |
| Monreal, I | 1 |
| Díez, J | 1 |
| Oldenburg, O | 1 |
| Schäfers, RF | 1 |
| Kuntz, S | 1 |
| Sack, S | 1 |
| Erbel, R | 1 |
| Philipp, T | 1 |
| Weber, F | 1 |
2 reviews available for losartan and Cardiomyopathies
| Article | Year |
|---|---|
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Topics: Adolescent; Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2018 |
Cardiac sarcoidosis: Case presentation and Review of the literature.
Topics: Cardiomyopathies; Cardiovascular Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressiv | 2019 |
1 trial available for losartan and Cardiomyopathies
| Article | Year |
|---|---|
[Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan | 2002 |
29 other studies available for losartan and Cardiomyopathies
| Article | Year |
|---|---|
Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Antihypertensive Agents; Cardiomyopathie | 2021 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; | 2022 |
Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.
Topics: Acetanilides; Animals; Cardiomyopathies; Cardiotoxicity; Doxorubicin; Losartan; Male; Rats; Rats, Wi | 2022 |
Losartan attenuates sepsis-induced cardiomyopathy by regulating macrophage polarization via TLR4-mediated NF-κB and MAPK signaling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotens | 2022 |
Integrin subunit β-like 1 mediates angiotensin II-induced myocardial fibrosis by regulating the forkhead box Q1/Snail axis.
Topics: Angiotensin II; Animals; Cardiomyopathies; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Int | 2022 |
An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy.
Topics: Angiotensin II; Animals; Cardiomyopathies; Cardiotonic Agents; Cell Line; Cell Survival; Coculture T | 2021 |
Acute AT
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathies; Dystrophin; Heart; Humans; Isopr | 2019 |
Impact of early life AT
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Biomarkers; Cardiomyopathies; Di | 2019 |
Renal denervation significantly attenuates cardiorenal fibrosis in rats with sustained pressure overload.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cardiomyo | 2016 |
N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster.
Topics: Acetylcysteine; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Benzylamines; Cardiomyop | 2008 |
Prolonged exposure of cardiac cells to renin plus angiotensinogen reduces intracellular renin in the failing heart. On the role of angiotensin II-AT1 complex internalization.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Cardiomyopathies; Cells, Cultured | 2009 |
Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Urea Nitrogen; Blotting, Western; Cardiomyop | 2009 |
Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathies; Cell Adhesion Mo | 2011 |
Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling.
Topics: Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, New | 2011 |
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Calcinosis; Cardiomyopathies; Echocardiography; Female; Humans; Hypertensio | 2013 |
Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Cardiomyopathies; Cells | 2002 |
Intracellular and extracellular angiotensin II enhance the L-type calcium current in the failing heart.
Topics: Adenosine Triphosphatases; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; A | 2004 |
Cardiomyopathy associated with celiac disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiomyopathies; Celiac Disease; Contraindications; | 2005 |
Angiotensin II-dependent vascular alterations in young cardiomyopathic hamsters: role for oxidative stress.
Topics: Acetylcysteine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Aort | 2006 |
Increased vascular angiotensin II binding capacity and ET-1 release in young cardiomyopathic hamsters.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Binding, Competit | 2006 |
Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol.
Topics: 14-3-3 Proteins; Angiotensin II; Animals; Apoptosis; Blood Glucose; Body Weight; Cardiomegaly; Cardi | 2006 |
Transient left ventricular dysfunction due to stress-induced cardiomyopathy.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; | 2007 |
Upregulation of cardiac angiotensin II AT1 receptors in congenital cardiomyopathic hamsters.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Cardiomy | 1995 |
Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biochemical Phen | 1995 |
Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan.
Topics: Animals; Biphenyl Compounds; Cardiomyopathies; Collagen; Collagenases; Cricetinae; Gelatinases; Gene | 1997 |
Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Blotting, Northern; Cardiomyopathies; | 1999 |
[Heart failure as a cardiac symptom of sarcoidosis. Successful treatment of heart failure with steroids, digitalis and an angiotensin-1-receptor antagonist in sarcoidosis].
Topics: Adult; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cardiomyopathies; Digitoxin; Drug Therapy, | 2000 |
Interaction between AT1 and alpha1-adrenergic receptors in cardiomyopathic hamsters.
Topics: Angiotensin I; Animals; Antihypertensive Agents; Aorta; Cardiomyopathies; Cricetinae; Disease Models | 2000 |
Chronic administration of losartan plus hydrochlorothiazide improves vascular status in young cardiomyopathic hamsters.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta, Thoracic; Body Weight; Cardiomyopathies; Cri | 2001 |